

NEWS RELEASE

For immediate release

Contact: Andrew Huff
847/382-7404

Sharla Costello
847/382-7404

EXPERTS NOTE BROAD UTILITY OF CLODERM IN TREATING A RANGE OF DERMATOSES

NEW ORLEANS (May 17, 2005) — Cloderm® (clocortolone pivalate 0.1%) Cream is useful in safely treating and managing a wide range of dermatoses, according to experts at a roundtable discussion during the recent meeting of the American Academy of Dermatology here.

"Cloderm is a good place to start when assessing any corticosteroid-responsive dermatosis," said Dr. Joseph Bikowski, clinical assistant professor of dermatology at the Ohio State University, and member of Coria Laboratories' Advisory Board. "It's an exceptionally versatile therapy that can achieve high efficacy with low risk."

Cloderm Cream is a unique mid-potency steroid in an emollient cream formulation that combines proven efficacy and rapid onset of action with an excellent

(more)

profile of safety and patient tolerability.

There are a host of disorders for which a mid-potency steroid therapy is appropriate, Dr. Bikowski noted, including seborrheic dermatitis, atopic dermatitis, dry skin eczema, also known as xerotic eczema, psoriasis and others.

"For example, in mild cases of psoriasis, especially psoriasis in areas where the skin folds or rubs against itself, Cloderm is useful in achieving a rapid response," Dr. Bikowski said. "After two to four weeks, it may be stopped and switched to a topical immune response modulator such as Protopic® (tacrolimus) Ointment."

Dr. Alan B. Fleischer, professor and chair, department of dermatology, Wake Forest University School of Medicine, noted that dermatologists have been very comfortable using a mid-potency halogenated steroid such as Cloderm, which in addition to its low side effect profile also has enhanced potency due to its unique combination of chlorine and fluorine atoms. "Because of its efficacy and excellent safety profile, clinicians are prescribing it for a large number of disorders," he said.

The most common adverse events with Cloderm include dryness, irritation, folliculitis, acneform eruptions and burning. Cloderm is contraindicated in patients who are hypersensitive to any of the ingredients of this product. As with all topical corticosteroids, systemic absorption can produce reversible HPA-axis suppression.

Cloderm Cream is available as a prescription product in 15-gram, 45-gram and 90-gram tubes at pharmacies nationwide, or by contacting Coria Laboratories, Ltd. at

(more)

866/819-9007.

Cloderm Cream is marketed by Coria Laboratories, Ltd., formerly known as Healthpoint Dermatology, a rapidly growing pharmaceutical company that specializes in research, development and marketing of branded prescription drugs and over-the-counter dermatology products.

#